Actively Recruiting
Evaluating Safety and Activity of New Drug Combinations for Advanced or Metastatic Non-Small Cell Lung Cancer
Led by AstraZeneca · Updated on 2026-10-15
278
Participants Needed
83
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating new combination treatments for people with locally advanced or metastatic non-small cell lung cancer NSCLC in this Phase II, multi-center, open-label study. The study includes several sub-studies focused on different groups based on tumor genetics and PD-L1 levels, aiming to assess the safety, tolerability, and early anti-tumor effects of these novel regimens. This global study is conducted at approximately 80 centers across 10 countries. Participants receive different combinations of investigational drugs given by intravenous infusion, including rilvegostomig, ramucirumab, and Dato-DXd, depending on their assigned sub-study. Treatments continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. Each sub-study may have a safety run-in phase followed by a dose expansion phase to further evaluate the treatments. Throughout the study, participants undergo regular assessments to monitor tumor response, side effects, and drug levels in the blood. Researchers will track adverse events and measure outcomes like objective response rate, progression-free survival, and overall survival over an average of three years. The study also evaluates pharmacokinetics and immune response to the treatments to better understand how they work and their safety profile.
CONDITIONS
Brief Title
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here